Mike is Senior Director and Co-Founder of Quench Bio. Prior to joining Quench, Mike worked at Tempero Pharmaceuticals from its launch and remained with the company through its acquisition and transition into the Immuno-Inflammation Therapy Area Unit at GSK. During this time Mike led projects in Th17, Treg, and innate immunology covering target identification, target validation and compound progression through in vitro and in vivo pharmacology and candidate selection. Mike began his career leading GPCR drug discovery programs in immunology and inflammation at Wyeth and Ascent Therapeutics, developing and implementing high content imaging assays for high-throughput screening and multiple biochemical and cell-based assays for lead optimization. Mike received a BS in Biophysics from SUNY Geneseo and a PhD in Pharmacology from the University of Washington before completing a postdoctoral fellowship at Wyeth. When not in the office, Mike loves spending time with his family and friends outdoors skiing, running and BBQ’ing.